 |
88 Diseases |  |
68 Trials |
|
68 Trials |  |
2888 News |  |
| «12...24252627282930313233343536» |
- ||| leflunomide / generics
Clinical: Thanks for the mention Dr. @jiseav! My mentions include #TSSMN @TSSMN @WomenInThoracic @STS_CTsurgery @AATSHQ @EACTS @annalsthorsurg @AATSJournals @ctsnetorg @CTSurgeryFdn @maraantonoff @AraVaporciyan @TomVargheseJr @DavidCookeMD @biniamkidaneMD @archerm2 @ShandaBlackmon #SoMe4CT (Twitter) - Oct 11, 2019
- | leflunomide / generics
Clinical, Journal: Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. (Pubmed Central) - Oct 10, 2019
Among the csDMARDs, leflunomide can be beneficial in lumbar spine BMD in RA patients with osteoporosis.
- | Orencia (abatacept) / BMS, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal, Combination therapy: Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs (Pubmed Central) - Oct 8, 2019
With regard to tolerability, apart from the classic side effects of MTX, there are no other significant differences concerning the combination of MTX and biologics. In case of MTX intolerance, leflunomide may be considered as an (unapproved) alternative.
- methotrexate / Generic Mfg.
Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease (B204) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_4011;
However, some SES measures were associated with increased Pain VAS, after simultaneously adjusting for all SES measures and covariates. These results are possibly due to the relatively short disease duration (5 years) and length of follow-up (4 years) of the population and warrants further research with longer periods of follow-up.
- Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis (B309) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3960;
P2b
Furthermore, there was a clear separation between TIL and PBO as early as 8 weeks for ACR20 (TIL 200 mg Q4W and 100 mg Q12W) and 12 weeks for both ACR20 (TIL 200 mg doses) and ACR50 (all TIL groups). Shortening the dosing interval from Q12W to Q4W for the 200-mg dose did not result in a measurable increase in skin or joint response scores.
- cyclophosphamide intravenous / Generic Mfg.
Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM) (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3514;
Patients with SLEDAI-2K≤4 score at baseline had a significantly higher retention rate of disease activity. The patients who performed more self-assessments through SSDM had lower probability of relapse and higher rate of T2T maintaining and achievement.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Xeljanz (tofacitinib) / Pfizer
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3473;
However, targeting one by one the suspected cytokines did not allow identifying a single responsible factor suggesting that a combination of several factors could be required. In the context of the NECESSITY project, further inhibition experiments with the combination of leflunomide and hydroxychloroquine and with inhibitors of specific B-cell mediators as Btk and Pi3K are planned and will be presented at the congress.
- hydroxychloroquine / Generic Mfg., Azulfidine (sulfasalazine) / Generic Mfg., hydroxychloroquine / VG Lifesciences
Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3448;
Creating a simple structured information card helped to address these deficiencies. The sustainability of this intervention will be measured.
- cyclophosphamide intravenous / Generic Mfg.
Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3447;
We identified no patient factors to predict the absence of counseling documentation in the remaining 27%. This underscores the need for additional work in larger samples to identify potential patient- and/or physician-related factors associated with a lack of reproductive counseling documentation as well as QI initiatives to improve documentation and counseling rates.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J
Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3434;
This project was supported by the National Natural Science Foundation of China (No.81571599). The workflow of proteomic analysis in this study.
- methotrexate / generics
The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3429;
In this registry study of patients with RA, use of MTX co-medication was associated with significantly better first TNFi drug survival compared to monotherapy. Disclaimer: This study was supported by the project of MHCR for conceptual development of research organization 00023728 Figure 1: Kaplan–Meier curves of 6-year drug survival of the first TNFi based on co-medication Table 1: Baseline patient characteristics
- Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3418;
The data from the clinical trials utilized in Table 1 and the practices contain heterogeneous populations of patients of unknown disease duration and dissimilar prior treatments. This study is observational, without the structure of a clinical trial, generated during routine clinical practice, and could qualify as real world data.
- Humira (adalimumab) / Eisai, AbbVie
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3416;
The management we do is aggressive and early with a diagnosis at first visit in 72.9% of patients. In 25% of patients treatment is prescribed from the moment of diagnosis and at least 50% of our patients are treated before a month from first visit.
- methotrexate / generics
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3414;
The objective of this pilot study was to assess the efficacy and safety of Biqi capsule, a Chinses herbal medicine combined with methotrexate (MTX) against patients with rheumatoid arthritis (RA) comparing with the combination therapy of MTX with Leflunomide (LEF). With a beneficial clinical response and acceptable tolerability, our study suggested that Biqi capsule appeared to be a promising alternative option in combination with MTX in RA treatment.
- methotrexate / generics
High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3408;
This study demonstrated clearly that the initial MTX dose up to 15 mg /week was not associated with an increased toxicity on liver in Korean patients with RA. Therefore, MTX can be started at 15 mg/week in Korean patients with RA without a safety concern on liver toxicity.
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche, Biogen
The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3396;
We found DMARDs to consistently lower the rate of cardiovascular events compared to unexposed patients. Although data is still limited, multiple studies reported that non-TNFi significantly lower cardiovascular event rates compared to TNFi.
- Humira (adalimumab) / Eisai, AbbVie
Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough? (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3227;
About half of RA patients for whom treatment was indicated never received an Osteoporosis medication. Our study shows the improper implementation of guidelines in our high-risk patient population which is consistent with previous studies.
- Actemra IV (tocilizumab) / Roche, JW Pharma, cyclophosphamide intravenous / Generic Mfg., Rituxan (rituximab) / Roche, Biogen
BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3078;
Likewise, there was no statistical difference in the frequency of BKV viremia or viruria by subject’s CTD diagnosis. These data suggest that immunologic control of BKV viremia and viruria may be dysregulated in CTD, independent of immunosuppressive regimens.
- tacrolimus / Generic Mfg., cyclophosphamide intravenous / Generic Mfg., Rituxan (rituximab) / Roche, Biogen
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3072;
Although, the exposure to ≥2 immunosuppressants was more than twice in cases than in controls, it was not significant in multivariable analysis. Prospective studies are needed to clarify the potential risk of immunosuppressants for TB infection development in SLE.
- Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Rituxan (rituximab) / Roche, Biogen
Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3056;
There was no statistically significant difference in CRP values in all patients, Rapid 3 scores in all patients, and Rapid 3 scores among rheumatoid arthritis patients before and after the HZ/su. 1.0 2.0
- leflunomide / generics
Efficacy of Leflunomide for Treatment of Vasculitis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2753;
No new safety signals for LEF were identified in this population. tab1 Table 1.
- Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2375;
Instead, they often used cDMARDs combination therapy. During the 1 year before initiating bDMARDs or JAKis, they were treated with intensive cDMARD combination therapy rather than escalating their MTX dose
- Xeljanz (tofacitinib) / Pfizer
Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2347;
Older age was associated with higher adherence. The agreement between the questionnaires CQR19 and CQR5 was low.
- leflunomide / generics
Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM) (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2342;
Through patterns extraction, data mining and modeling, a master algorithm of efficacy prediction and decision making for RA were developed. Following data inputting and machine leaning, an artificial intelligent system in assisting clinical practice may be achieved with SSDM.
- Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2320;
Possible reasons include the rapid increase in availability of bDMARDs between and across classes and increased uptake and confidence in bDMARD use by prescribing rheumatologists over time. Further work to evaluate the impact of bDMARD prescription patterns on patients and society is planned.
- Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2181;
Previous therapies included corticosteroids (83%) , methotrexate (66%), TNF inhibitor drug (44%), azathioprine (20.8%), mycophenolate (12%), cyclophosphamide (8%), rituximab (10%), hydroxychloroquine (6%), anakinra in 2 patients and interferon, dapsone, etoposide, leflunomide, abatacept, salazopyrin or intra-venous immunoglobulin in 1 patient each. In conclusion, TCZ is used off-label in daily practice to treat various refractory autoimmune diseases with a good short-term efficacy and tolerance.
- azathioprine orodispersible / Generic Mfg.
Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2110;
Given the lower rate of awareness provided by Rheumatologists about the flu shot in comparison to primary providers, we propose more patient education on the part of Rheumatologists on the need for influenza vaccination and on the perceived lack of inefficacy of the influenza vaccine. More studies should evaluate factors that contribute to the relatively high coverage rate seen in RA and SLE patients.
- methotrexate / generics, leflunomide / generics
Deep Learning Social Media Analysis Demonstrated Gender-Specific Disparity in Side Effects from Rheumatoid Medications (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2069;
Although social media may reflect biased prevalence of conditions due to subjective user behaviors, we were able to faithfully describe the data. In addition to improving our methods, future work will emphasize verifying/comparing such disparity by applying similar analysis on EHRs along with generic social media (e.g., Twitter, Google+, and reddit).
- Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2044;
Two conventional DMARDs had substantial unit cost increases, but their expenditure level remained a fraction (3%) of total DMARD spending. While not all of the biologics were used for RA, these increases should be carefully considered relative to their clinical benefit.
- Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018 (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1989;
cDMARD use remained consistent and IL therapy use increased second line. Introduction of newer PsA agents has impacted the treatment paradigm.
- Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database (A411-A412) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1839;
Except for prostate cancer in men, which occurred less frequently in biologics treated patients. The reason of this difference remains unclear, but could be linked to a high frequency of screening before introducing biologic.
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche, Biogen
Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease () - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1824;
In our study, for RA-LD mortality, UIP pattern is usual suspected risk factor and pleural effusion, shorter time-interval between diagnosis RA and RA-LD are newly defined strong predictors. These risk factors may be used in the early risk stratification in the management of RA-LD routine practice.
- cyclophosphamide intravenous / Generic Mfg.
Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1769;
Treatment with LEF in TA can achieve clinical remission in a short period of time, and maintain long-term stability of the disease, especially for refractory patients. LEF presents safety for women of childbearing age, and can be used for long-term treatment of patients with TA.
- tacrolimus / Generic Mfg.
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1443;
In the early phase of reduction, synovitis was an important factor in disease flare, and as reduction became long-term, bone erosion was also important. We conclude that half-dose reduction of MTX in RA patients who achieve clinical remission and have low total RAMRIS scores might be a beneficial option for tapering MTX.
- methotrexate / generics, leflunomide / generics
Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1421;
In mice, the generation of arthritis induced inflammation, fibrosis, endoplasmic reticulum and oxidative stress and an alteration in glucose and lipid metabolisms in the liver. Methotrexate could affect the hepatic function as long as there is a subclinical pre-existent alteration of the liver such as obesity.
- tacrolimus / Generic Mfg., cyclophosphamide intravenous / Generic Mfg., Rituxan (rituximab) / Roche, Biogen
Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1282;
NSIP and NSIP/OP were the most prevalent HRCT patterns. Worse baseline PF could be related to the absence of extra-thoracic symptoms and "classic" antibodies of CTD (e.g ANA, Ro), causing delay in diagnosis and treatment.
- hydroxychloroquine / Generic Mfg., hydroxychloroquine / VG Lifesciences, celecoxib oral / Generic Mfg.
Develop Risk Prediction Model and Drug Withdrawl Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM) (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1130;
Via continuing data inputs and machine leaning, an artificial intelligent system in assisting clinical forecast and decision-making may be achieved with SSDM. Fig.1 AE rate of combination regiment with that of MTX monotherapy Fig.2 Bayesian network and date processing:Patients number (black as blow) and the rate of LP,IP and ALT elevation in 31 regiments.
- methotrexate / generics, leflunomide / generics
Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1073;
However, when analyzing biomarker predictors of radiographic progression, CCP, RFIgM, RFIgA, and SE are not significantly associated with disease progression in African Americans over a 60-month disease duration with early RA. Future larger longitudinal studies are needed to confirm our results.
- ||| leflunomide / generics
Clinical: Very eager to hear your thoughts on the following! @WomenSurgeons @WomenInThoracic @DavidCookeMD @DrKathyHughes @drnikkistamp @susieQP8 @AraVaporciyan @AcademicSurgery @ShandaBlackmon @LisaBrownMD @OPreventzaMD @roberthiggins32 @RUBraveEnough @choo_ek @TomVargheseJr (Twitter) - Oct 3, 2019
- || leflunomide / generics
Would love if you can join on the upcoming #TSSMN #TweetChat - Ping @DVervoort94 @JackieKOlive @tamaranihici @archerm2 @ahalpernunc @elde_md @LisaBrownMD @ShandaBlackmon @Cerf_MD @ctsnetorg @CTSurgeryFdn @TSRA_official @OfficialSTSA @atscommunity @AraVaporciyan @DouglasEWood1 (Twitter) - Oct 3, 2019
- | sulfasalazine / Generic mfg., leflunomide / Generic mfg.
Trial completion, Phase classification, Monotherapy: Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy (clinicaltrials.gov) - Sep 30, 2019
P3, N=136, Completed, Sponsor: Jawaharlal Institute of Postgraduate Medical Education & Research
Future larger longitudinal studies are needed to confirm our results. Recruiting --> Completed | Phase classification: P4 --> P3
- |||| leflunomide / generics
Very proud of our resident @ErinMCorsiniMD, who won 2nd place at the @AATSHQ #ITSOS2019 with our @MDAndersonNews study evaluating impact of primary colorectal cancer laterality on outcomes after pulmonary metastesectomy. Outstanding job, Erin! @AraVaporciyan @VanMorrisMD (Twitter) - Sep 28, 2019
- | cisplatin / generics
Journal: Comparison of Pregnane X Receptor Antagonists for Enhancing the Antitumor Effect of Cisplatin. (Pubmed Central) - Sep 27, 2019
Recruiting --> Completed | Phase classification: P4 --> P3 These results suggested that ketoconazole and PEITC enhance the antitumor activity of platinum compounds by different and complex mechanisms.
- | fluorouracil / generics
Journal, Combination therapy: UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. (Pubmed Central) - Sep 27, 2019
Human tumor xenograft studies showed that LFN treatment reduces growth of established tumors when used in combination with a genotoxic agent, 5-fluorouracil (5-FU). Our data suggest that DHODH is a promising target for chemoprevention and combination therapy of UVB-induced cSCCs.
- |||| leflunomide / generics
Clinical: In case you missed the opening of our newest center - take a peek @TheWoodlandsMPC @TheTownshipTX @MDAndersonNews #Cancers #cancertreatment @ACKoongMDPhD @SteveHahnMD @maraantonoff @AraVaporciyan @KellyKhunt @JoeHermanMD @AlyssaRieber @NSchecht (Twitter) - Sep 27, 2019
- | leflunomide / generics
Journal: Tree growth and water-use in hyper-arid Acacia occurs during the hottest and driest season. (Pubmed Central) - Sep 26, 2019
Stem diameter dynamics, leaf phenology, and sap flow were monitored during 3 consecutive years in five Acacia raddiana trees and five Acacia tortilis trees in the Arid Arava Valley, southern Israel (annual precipitation 20-70 mm, restricted to October-May)...These findings point to the possibility that summer cambial growth in Acacia under hyper-arid conditions relies on concurrent leaf gas exchange, which is in turn permitted by access to deep soil water. Soil water can support low-density tree populations despite heat and drought, as long as recharge is kept above a minimum threshold.
- | Xeljanz (tofacitinib) / Pfizer
Clinical, Journal: Tofacitinib in the treatment of active rheumatoid arthritis - single-centre experience. (Pubmed Central) - Sep 25, 2019
Despite the observed adverse effects, in the light of the available data tofacitinib demonstrates a favourable safety profile. JAK kinase inhibitors - a new class of drugs - will enable a wider population of patients to achieve remission or low disease activity.
- prednisone / generics, leflunomide / generics
NECROBIOTIC LUNG NODULE: AN UNUSUAL PRESENTATION OF RHEUMATOID ARTHRITIS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 3) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3756;
There are many etiologies of pulmonary nodules, and therefore, it is imperative to keep a wide differential diagnosis. In patients with RA and subcutaneous nodules, the possibility of necrobiotic lung nodule should be included in the differential diagnosis.
- methotrexate / generics, leflunomide / generics
RARE PRESENTATION OF LUNG DISEASE IN RHEUMATOID ARTHRITIS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2821;
There is a need to formulate new studies to gather data on newly diagnosed disease with rapidly progressing lung cavitations. The high frequency of Leflunomide therapy in patients with RA with cavitary pulmonary nodules should also be emphasized.
- hydroxychloroquine / Generic Mfg., Desoxyn (methamphetamine) / Lundbeck, hydroxychloroquine / VG Lifesciences
CHYLOPYOPNEUMOTHORAX IN A PATIENT WITH RHEUMATOID LUNG DISEASE (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_1574;
They should be considered in the differential when an immunocompromised individual with chronic lung disease presents with acute worsening. We describe a rare association of rheumatoid lung disease with M. fortuitum pulmonary infection which lead to acute presentation with chylopyopneumothorax.